

CITATION REPORT

List of articles citing

Multiple myeloma

DOI: 10.1182/blood-2007-10-078022
Blood, 2008, 111, 2962-72.

Source: <https://exaly.com/paper-pdf/44893055/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
724	Historie des multiplen Myeloms. 2008 , 1, 21-22		
723	Newly developed effective anti-cancer drugs targeting multiple myeloma. 2008 , 69, 451-459		1
722	Frontline treatment of multiple myeloma in elderly patients. 2008 , 22, 303-9		9
721	Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. 2008 , 22, 1604-12		75
720	Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. 2008 , 2, 317-26		58
719	Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. <i>Blood</i> , 2008 , 112, 4384-99	2.2	283
718	¹⁵³ Sm: its use in multiple myeloma and report of a clinical experience. 2008 , 17, 1379-87		14
717	Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. <i>Blood</i> , 2008 , 112, 3403-11	2.2	62
716	Analysis of clonotypic switch junctions reveals multiple myeloma originates from a single class switch event with ongoing mutation in the isotype-switched progeny. <i>Blood</i> , 2008 , 112, 1894-903	2.2	13
715	TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA. 26-36		
714	Current and emerging treatments for multiple myeloma. 2008 , 14, 12-9		19
713	[Orbital tumor as the first clinical manifestation of multiple myeloma: case report]. 2009 , 72, 106-8		
712	Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. 2009 , 2009, 867380		15
711	A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma. 2009 , 15, 1069-75		35
710	Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma. 2009 , 27, 5001-7		42
709	Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation. 2009 , 183, 4385-94		65
708	Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines. 2009 , 15, 2808-17		50

707	Apo2L/TRAIL inhibits tumor growth and bone destruction in a murine model of multiple myeloma. 2009 , 15, 1998-2009	30
706	Clinical features and survival outcomes in patients with multiple myeloma: analysis of web-based data from the Korean Myeloma Registry. 2009 , 122, 200-10	27
705	Initial therapy in multiple myeloma: investigating the new treatment paradigm. 2009 , 15, 131-41	2
704	Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. 2009 , 9, 854-70	19
703	Emerging therapies for multiple myeloma. 2009 , 14, 99-127	40
702	Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. 2009 , 27, 5015-22	67
701	Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma. 2009 , 315, 2471-8	12
700	Influx and efflux transport as determinants of melphalan cytotoxicity: Resistance to melphalan in MDR1 overexpressing tumor cell lines. 2009 , 78, 45-53	38
699	Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. 2009 , 625, 6-22	18
698	Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. 2009 , 125, 2147-50	55
697	The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. 2009 , 115, 2155-64	8
696	Centrosomes and myeloma; aneuploidy and proliferation. 2009 , 50, 697-707	11
695	A retrospective analysis of bortezomib therapy for Japanese patients with relapsed or refractory multiple myeloma: beta2-microglobulin associated with time to progression. 2009 , 89, 342-347	9
694	Overexpression of Annexin II affects the proliferation, apoptosis, invasion and production of proangiogenic factors in multiple myeloma. 2009 , 90, 177-185	77
693	Multiples Myelom. 2009 , 4, 4-13	1
692	Correlation of high-resolution X-ray micro-computed tomography with bioluminescence imaging of multiple myeloma growth in a xenograft mouse model. 2009 , 85, 434-43	7
691	Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. 2009 , 145, 151-63	75
690	Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. 2009 , 145, 569-80	94

689	Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800. 2009 , 147, 319-27	15
688	DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway. 2009 , 23, 383-90	35
687	Proteasome inhibitors in the treatment of multiple myeloma. 2009 , 23, 1964-79	140
686	Spotlight review series on multiple myeloma. 2009 , 23, R1-R2	0
685	High-dose chemotherapy with autologous stem cell transplantation for multiple myeloma: what predicts the outcome? Experience from a developing country. 2009 , 43, 481-9	14
684	Plasma cell neoplasms. 2009 , 15, 134-141	0
683	Elucidation of potential bortezomib response markers in multiple myeloma patients. 2009 , 49, 115-22	15
682	Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. 2009 , 8, 3006-19	51
681	Development of vorinostat: current applications and future perspectives for cancer therapy. 2009 , 280, 201-10	135
680	Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. 2009 , 15, 463-70	46
679	Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. 2009 , 15, 718-23	124
678	Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. 2009 , 15, 1386-93	16
677	Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count. 2009 , 42, 71-6	8
676	Natural killer and gammadelta T cells in haematological malignancies: enhancing the immune effectors. 2009 , 15, 275-84	41
675	Treatment of multiple myeloma: a comprehensive review. 2009 , 9, 278-88	117
674	Acute myeloid leukemia complicating multiple myeloma: a case successfully treated with etoposide, thioguanine, and cytarabine. 2009 , 9, E14-5	4
673	Extramedullary plasmacytoma of the pancreas as an uncommon cause of obstructive jaundice: a case report. 2009 , 3, 8785	16
672	Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. 2009 , 27, 3664-70	322

671	Single or Double Autologous Stem Cell Transplantation Before and After the Era of Novel Agents. 2009 , 9, S51-S52		
670	Curing Multiple Myeloma: Lessons from Total Therapy Protocols. 2009 , 9, S52-S54		
669	Análisis interlaboratorio de parámetros inmunológicos, paraproteínas y bandas oligoclonales. Informe técnico del IV Taller de Inmunología de la Sociedad Española de Inmunología. 2009 , 28, 79-95		
668	54-year-old woman with fatigue, back pain, and hypercalcemia. 2009 , 84, e9-e12		
667	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. 2009 , 84, 1095-110		199
666	Plasma cell myeloma. 2009 , 23, 709-27		15
665	Bibliography. Current world literature. 2009 , 21, 177-89		
664	Interférons: utilisation thérapeutique. 2009 , 4, 1-6		
663	ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. <i>Blood</i> , 2009 , 113, 3503-11	2.2	325
662	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009 , 113, 3375-82	2.2	81
661	Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols. <i>Blood</i> , 2009 , 114, 1299-305	2.2	83
660	Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. 2009 , 94, 270-5		107
659	The Belgian 2010 consensus recommendations for the treatment of multiple myeloma. 2010 , 65, 252-64		
658	Lenalidomide for the treatment of cryoglobulinemia and undifferentiated spondyloarthropathy in a patient with multiple myeloma. 2010 , 16, 90-1		8
657	Busulfan 12 mg/kg plus melphalan 140 mg/m ² versus melphalan 200 mg/m ² as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. 2010 , 95, 1913-20		83
656	A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. 2010 , 95, 845-8		115
655	Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8 ⁺ T cells and characterize the progression of MGUS to multiple myeloma. <i>Blood</i> , 2010 , 115, 1185-93	2.2	48
654	Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. <i>Blood</i> , 2010 , 115, 3655-63	2.2	102

653	Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multitarget mechanism discovered through systematic combination screening in B-cell malignancies. <i>Blood</i> , 2010 , 116, 593-602	2.2	22
652	Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. <i>Blood</i> , 2010 , 116, 1524-7	2.2	113
651	In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. <i>Blood</i> , 2010 , 116, 3635-44	2.2	97
650	Comparison of a new whole-body continuous-table-movement protocol versus a standard whole-body MR protocol for the assessment of multiple myeloma. 2010 , 20, 2907-16		13
649	Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. 2010 , 9, 176		83
648	The hemopoietic stem cell niche versus the microenvironment of the multiple myeloma-tumor initiating cell. 2010 , 3, 15-28		29
647	New targets of PS-341: BAFF and APRIL. 2010 , 27, 439-45		8
646	Treatment of newly diagnosed multiple myeloma: advances in current therapy. 2010 , 27 Suppl 1, S14-24		9
645	Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma. 2010 , 92, 83-94		17
644	Bortezomib plus dexamethasone for relapsed or treatment refractory multiple myeloma: the collaborative study at six institutes in Kyoto and Osaka. 2010 , 92, 579-86		11
643	The DAC system and associations with multiple myeloma. 2010 , 28 Suppl 1, S28-35		14
642	Therapeutic options in the management of myeloma bone disease. 2010 , 37 Suppl 1, S20-9		7
641	De-regulated FGF receptors as therapeutic targets in cancer. 2010 , 125, 105-17		140
640	Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. 2010 , 84, 201-11		48
639	Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma. 2010 , 84, 337-44		35
638	Extensive soft-tissue involvement by plasmablastic myeloma arising from displaced humeral fractures. 2010 , 85, 448-51		19
637	Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes. 2010 , 34, 742-51		20
636	Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. 2010 , 34, 1111-8		49

635	Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myeloma. 2010 , 148, 853-8	2
634	Expression and function of toll-like receptors in multiple myeloma patients: toll-like receptor ligands promote multiple myeloma cell growth and survival via activation of nuclear factor-kappaB. 2010 , 150, 543-53	36
633	DNA vaccines to target the cancer testis antigen PASD1 in human multiple myeloma. 2010 , 24, 1951-9	16
632	Correlation between array-comparative genomic hybridization-defined genomic gains and losses and survival: identification of 1p31-32 deletion as a prognostic factor in myeloma. 2010 , 24, 833-42	38
631	Blood Disorders in the Elderly. 2010 , 775-790	
630	Robert Arthur Kyle, MD: a conversation with the editor. 2010 , 23, 400-18	
629	Multiple myeloma with monoclonal free IgG3 heavy chains and free kappa light chains. 2010 , 123, 158-61	6
628	Current concepts in the evaluation of multiple myeloma with MR imaging and FDG PET/CT. 2010 , 30, 127-42	109
627	Infection and killing of multiple myeloma by adenoviruses. 2010 , 21, 179-90	38
626	Effect of proteasome inhibitors with different chemical structures on the ubiquitin-proteasome system in vitro. 2010 , 47, 358-67	11
625	Free Ig light chains interact with sphingomyelin and are found on the surface of myeloma plasma cells in an aggregated form. 2010 , 185, 4179-88	19
624	Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. 2010 , 7, 289-94	15
623	Attainment of at least a very good partial response after induction treatment is an important surrogate of longer survival for multiple myeloma. 2010 , 45, 1625-30	7
622	How to treat multiple myeloma - a representative multicentre treatment survey. 2010 , 33, 604-10	2
621	Calcium channel blocker verapamil enhances endoplasmic reticulum stress and cell death induced by proteasome inhibition in myeloma cells. 2010 , 12, 550-61	37
620	Prevalence of monoclonal gammopathy of undetermined significance: a systematic review. 2010 , 85, 933-42	88
619	Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes. 2010 , 182, 1-30	89
618	Vorinostat plus bortezomib for the treatment of relapsed/refractory multiple myeloma: a case series illustrating utility in clinical practice. 2010 , 10, 149-51	28

617	Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future. 2010 , 10, 248-57		15
616	Myeloma Bone Disease. 2010 ,		2
615	Anaesthetic management of a pregnant patient with multiple myeloma. 2010 , 19, 336-9		10
614	Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis. 2010 , 46, 1790-9		28
613	"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma. 2010 , 16, 70-7		5
612	Reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed multiple myeloma. 2010 , 16, 1122-9		31
611	Venous thromboembolism in patients with acute leukemia, lymphoma, and multiple myeloma. 2010 , 125 Suppl 2, S96-102		34
610	Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. 2010 , 11, 29-37		760
609	Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. 2010 , 11, 1086-95		167
608	Optimising bortezomib in newly diagnosed multiple myeloma. 2010 , 11, 909-10		5
607	INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support. 2010 , 12, 28-38		60
606	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1424-43	1.9	43
605	Matrine induces apoptosis of human multiple myeloma cells via activation of the mitochondrial pathway. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1337-46	1.9	27
604	Bortezomib for previously untreated multiple myeloma. 2011 , 12, 2553-64		7
603	Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma. <i>Blood</i> , 2011 , 118, 2985-7	2.2	27
602	Intérêt de la TEP/TDM dans le bilan d'extension et le suivi des lésions osseuses du myélome multiple. 2011 , 35, 239-254		
601	Multiple myeloma: current perspectives. 2011 , 31, 699-724, x		6
600	Evidence of a role for the novel zinc-finger transcription factor ZKSCAN3 in modulating Cyclin D2 expression in multiple myeloma. 2011 , 30, 1329-40		37

599	Autologous stem-cell transplantation for multiple myeloma: a Brazilian institution experience in 15 years of follow-up. 2011 , 9, 119-23		2
598	Quick detection of overexpressed genes caused by myeloma-specific chromosomal translocations using multiplex RT-PCR. 2011 , 27, 789-94		
597	Adenovirus as a new agent for multiple myeloma therapies: Opportunities and restrictions. 2011 , 46, 229-38		10
596	TLR9 ligand induces the generation of CD20+ plasmablasts and plasma cells from CD27+ memory B-cells. 2011 , 2, 83		24
595	Epigenetic inactivation of the miR-124-1 in haematological malignancies. 2011 , 6, e19027		99
594	Type 1 cryoglobulinemia: response to thalidomide and lenalidomide. 2011 , 17, 145-7		11
593	Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival. <i>Blood</i> , 2011 , 117, 1998-2004	2.2	72
592	Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. <i>Blood</i> , 2011 , 117, 4691-5	2.2	681
591	IgM multiple myeloma presenting with bleeding tendency: a case report with immunophenotype analysis. 2011 , 2, 55-57		1
590	Pegylated liposomal doxorubicin for multiple myeloma. 2011 ,		
589	Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. 2011 , 154, 755-62		17
588	KRN5500, a spicamycin derivative, exerts anti-myeloma effects through impairing both myeloma cells and osteoclasts. 2011 , 155, 328-39		5
587	Healthcare costs of multiple myeloma: an Italian study. 2011 , 20, 330-6		12
586	Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF- κ B and STAT3 regulated gene products in multiple myeloma cells. 2011 , 164, 1506-21		103
585	PBOX-15, a novel microtubule targeting agent, induces apoptosis, upregulates death receptors, and potentiates TRAIL-mediated apoptosis in multiple myeloma cells. 2011 , 104, 281-9		25
584	The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival. 2011 , 25, 538-50		95
583	Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. 2011 , 25, 906-8		131
582	Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing. 2011 , 86, 385-95		9

581	Lambda light chain multiple myeloma presenting as pleural mass. 2011 , 4, 12-14	0
580	Induction of myeloma-specific cytotoxic T lymphocytes responses by natural killer cells stimulated-dendritic cells in patients with multiple myeloma. 2011 , 35, 1241-7	9
579	Renal Disease in Hematological Malignancies. 2011 , 13, 5-18	
578	Cyclic AMP induces apoptosis in multiple myeloma cells and inhibits tumor development in a mouse myeloma model. 2011 , 11, 301	30
577	Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. 2011 , 140, 160-6	43
576	Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. 2011 , 29, 3805-12	229
575	Living with multiple myeloma: experiences of patients and their informal caregivers. 2011 , 19, 101-11	74
574	Polyclonal rabbit anti-murine plasmacytoma cell globulins induce myeloma cells apoptosis and inhibit tumour growth in mice. 2011 , 16, 370-81	4
573	Platelet factor-4 and its p17-70 peptide inhibit myeloma proliferation and angiogenesis in vivo. 2011 , 11, 261	17
572	Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management. 2011 , 86, 57-65	109
571	Effectiveness and safety of high-dose cyclophosphamide as salvage therapy for high-risk multiple myeloma and plasma cell leukemia refractory to new biological agents. 2011 , 86, 699-701	4
570	Infrequent occurrence of MPL exon 10 mutations in polycythemia vera and post-polycythemia vera myelofibrosis. 2011 , 86, 701-2	21
569	Laboratory and echocardiography markers in sickle cell patients with leg ulcers. 2011 , 86, 705-8	34
568	Novel CUX1 missense mutation in association with 7q- at leukemic transformation of MPN. 2011 , 86, 703-5	19
567	Myeloablative allogeneic stem cell transplantation for lymphoblastic lymphoma in Sweden: a retrospective study. 2011 , 86, 709-10	4
566	Acquired factor V inhibitor complicating warfarin therapy. 2011 , 86, 710-2	7
565	Intra-arterial methylprednisolone for the management of steroid-refractory acute gastrointestinal and hepatic graft versus host disease. 2011 , 86, 712-4	5
564	Acquired Glanzmann's thrombasthenia with optimal response to rituximab therapy. 2011 , 86, 715-6	9

563	Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. 2011 , 117, 336-42		102
562	Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. 2011 , 96, 1512-20		42
561	Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma. 2011 , 6, 1047-52		21
560	Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1727-35	1.9	9
559	Lower incidence of plasma cell neoplasm is maintained in migrant Chinese to British Columbia: findings from a 30-year survey. <i>Leukemia and Lymphoma</i> , 2011 , 52, 2316-20	1.9	5
558	Solution densities and estimated total protein contents associated with inappropriate flotation of separator gel in different blood collection tubes. 2011 , 135, 1081-4		15
557	The bone marrow stroma in hematological neoplasms--a guilty bystander. 2011 , 8, 456-66		37
556	Factors associated with recovery of renal function in patients with multiple myeloma who were treated with hemodialysis. 2011 , 117, c28-32		5
555	Proteomics: addressing the challenges of multiple myeloma. 2011 , 43, 89-95		7
554	Bortezomib-dexamethasone or vincristine-doxorubicin-dexamethasone as induction therapy followed by thalidomide as maintenance therapy in untreated multiple myeloma patients. 2011 , 39, 1975-84		9
553	Change in expression pattern of TCR-CD3 complex in patients with multiple myeloma. 2011 , 16, 143-50		14
552	MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin. 2011 , 17, 4309-19		72
551	Treatment of multiple myeloma. 2011 , 8, 479-91		205
550	Three palonosetron regimens to prevent CINV in myeloma patients receiving multiple-day high-dose melphalan and hematopoietic stem cell transplantation. 2011 , 22, 939-946		29
549	Cancer/Testis Antigen MAGE-C1/CT7: new target for multiple myeloma therapy. 2012 , 2012, 257695		21
548	What's in a name? Bence Jones protein. 2012 , 5, 478-83		4
547	N-Propionyl polysialic acid precursor enhances the susceptibility of multiple myeloma to antitumor effect of anti-NprPSA monoclonal antibody. 2012 , 33, 1557-62		2
546	CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. 2012 , 26, 2135-41		52

545	Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. <i>Leukemia and Lymphoma</i> , 2012 , 53, 275-81	1.9	12
544	Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. 2012 , 11, 1432-42		12
543	Intrapleural bortezomib for the therapy of myelomatous pleural effusion: a case report. 2012 , 2012, 978479		6
542	Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. 2012 , 5, 763-71		41
541	Simultaneous targeting of PI3K and mTOR with NVP-BGT226 is highly effective in multiple myeloma. 2012 , 23, 131-8		36
540	Initial finding of mandible mass in multiple myeloma. 2012 , 23, e599-600		4
539	Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model. 2012 , 97, 1020-8		47
538	Myeloma cells contain high levels of inorganic polyphosphate which is associated with nucleolar transcription. 2012 , 97, 1264-71		60
537	The hypoxia-mimetic agent cobalt chloride induces cell cycle arrest and alters gene expression in U266 multiple myeloma cells. 2012 , 30, 1180-6		26
536	Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. <i>Blood</i> , 2012 , 119, 826-37	2.2	68
535	Successful bortezomib treatment in combination with dexamethasone and thalidomide for previously untreated epidural plasmacytoma. 2012 , 3, 557-559		5
534	Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. 2012 , 159, 430-40		38
533	An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. 2012 , 158, 739-48		144
532	Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity. 2012 , 170, 167-77		32
531	Novel agents derived from the currently approved treatments for MM: novel proteasome inhibitors and novel IMiDs. 2012 , 21, 1075-87		15
530	YM-175 induces apoptosis of human native monocyte-lineage cells via inhibition of prenylation. 2012 , 87, 1084-8		4
529	Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation. 2012 , 61, 1639-51		16
528	Myeloma kidney: improving clinical outcomes?. 2012 , 19, 342-51		9

527	Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. 2012 , 34, 257-62		
526	The role of natural killer cells in immunity against multiple myeloma. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1666-76	1.9	53
525	Current concepts of clinical management of multiple myeloma. 2012 , 58, 195-207		11
524	Advancing medicine one research note at a time: the educational value in clinical case reports. 2012 , 5, 293		24
523	Risk factors for unsuccessful peripheral blood stem cell harvesting using granulocyte-colony stimulating factor mobilization in patients with multiple myeloma. 2012 , 47, 331-5		9
522	Plasma cell myeloma associated with Epstein-Barr virus infection in an 11-year-old girl. 2012 , 15, 339-42		12
521	Response to salvage therapies and outcome in patients with multiple myeloma relapsing after pomalidomide therapy. 2012 , 26, 839-41		10
520	Radiological Imaging in Metastatic Bone Disease and Myeloma: Current Status and Limitations. 2012 , 173-194		
519	Impact of tandem autologous stem cell transplantation and response to transplant in the outcome of multiple myeloma. 2012 , 1, 35		3
518	Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma. 2012 , 107, 1987-96		114
517	Spontaneous acute subdural hematoma in a patient with multiple myeloma. 2012 , 01, 152-154		
516	Looking at CER from Medicare's perspective. 2012 , 18, S5-8		4
515	Autologous stem cell transplantation in Kuwait cancer control centre: Review of infections in the first thirty days post-transplant. 2012 , 2,		
514	Analysis of Multiple Myeloma Life Expectancy Using Copula. 2012 , 2,		1
513	Regulatory Cells and Multiple Myeloma. 2012 ,		1
512	Evaluation of chromosomal abnormalities by clg-FISH and association with proliferative and apoptotic indexes in multiple myeloma. 2012 , 45, 1074-9		4
511	Myeloma as a model for the process of metastasis: implications for therapy. <i>Blood</i> , 2012 , 120, 20-30	2.2	139
510	Durable remission with salvage second autotransplants in patients with multiple myeloma. 2012 , 118, 3549-55		63

509	Multiple myeloma-related deregulation of bone marrow-derived CD34(+) hematopoietic stem and progenitor cells. <i>Blood</i> , 2012 , 120, 2620-30	2.2	66
508	Monosomy 13 in metaphase spreads is a predictor of poor long-term outcome after bortezomib plus dexamethasone treatment for relapsed/refractory multiple myeloma. 2012 , 95, 516-26		12
507	CpG or IFN- γ are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. 2012 , 61, 561-71		18
506	Head and neck amyloidosis: clinicopathological features and immunohistochemical analysis of 14 cases. 2012 , 41, 178-85		28
505	The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. 2012 , 88, 1-7		6
504	Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. 2012 , 43, 1094-104		36
503	Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. 2012 , 87, 78-88		106
502	Thrombotic complications in multiple myeloma: a report of three cases and review of the literature. 2012 , 33, 197-201		4
501	Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. 2013 , 48, 1033-9		27
500	Fe ₃ O ₄ nanoparticle loaded paclitaxel induce multiple myeloma apoptosis by cell cycle arrest and increase cleavage of caspases in vitro. 2013 , 15, 1		2
499	A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors. 2013 , 13, 31		42
498	Plasma cell disorders in HIV-infected patients: epidemiology and molecular mechanisms. 2013 , 1, 8		26
497	Multiple myeloma-initiating cells. 2013 , 97, 306-12		22
496	Bortezomib, dexamethasone, and high-dose melphalan as conditioning for stem cell transplantation in young Japanese multiple myeloma patients: a pilot study. 2013 , 29, 147-51		3
495	Salvage second hematopoietic cell transplantation in myeloma. 2013 , 19, 760-6		87
494	Osteoporosis and cancer. 2013 , 11, 163-70		48
493	Initial treatment of nontransplant patients with multiple myeloma. 2013 , 40, 577-84		6
492	Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells. 2013 , 37, 1322-8		18

491	The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-multiple myeloma effects. 2013 , 27, 430-40		98
490	Imaging of multiple myeloma: usefulness of MRI and PET/CT. 2013 , 34, 566-77		9
489	Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL. 2013 , 13, 122		11
488	Molecular mechanisms of effectiveness of novel therapies in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013 , 54, 229-41	1.9	14
487	Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. <i>Blood</i> , 2013 , 121, 4493-503	2.2	27
486	Diagnosis and Treatment of Multiple Myeloma. 2013 , 637-663		2
485	Sphingosine-1-phosphate activates chemokine-promoted myeloma cell adhesion and migration involving $\alpha_4\beta_1$ integrin function. 2013 , 229, 36-48		21
484	Tumor cells loaded with β -galactosylceramide promote therapeutic NKT-dependent anti-tumor immunity in multiple myeloma. 2013 , 156, 132-9		14
483	Traitement du myélome multiple. 2013 , 34, A11-A15		
482	Three-dimensional Nuclear Telomere Organization in Multiple Myeloma. 2013 , 6, 749-56		14
481	Sequential signs of palpitation, bloody multiple cavity membrane effusion, and myocardial infarction: a case report of multiple myeloma and a literature review. 2013 , 13, 499-501		
480	Hematopoietic and microenvironment alterations in bone marrow from patients with multiple myeloma. 2013 , 37, 228-9		5
479	Formation of assemblies on cell membranes by secreted proteins: molecular studies of free λ light chain aggregates found on the surface of myeloma cells. 2013 , 454, 479-89		10
478	Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. 2013 , 88, 360-76		341
477	Autologous stem cell transplantation for multiple myeloma: identification of prognostic factors. 2013 , 13, 32-41		12
476	The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma. 2013 , 160, 465-76		50
475	Multiple myeloma: 2013 update on diagnosis, risk-stratification, and management. 2013 , 88, 226-35		92
474	Cytokines and Signal Transduction in Multiple Myeloma. 2013 , 535-546		2

473	Multiple Myeloma and the Kidney. 2013 , 619-629		
472	Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. 2013 , 32, 4191-202		61
471	CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFN γ cytokines and proliferation. 2013 , 2013, 564687		8
470	Quality of life and supportive care in multiple myeloma. 2013 , 30, 234-46		24
469	Understanding Leukemias, Lymphomas and Myelomas. 2013 ,		2
468	Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro. 2013 , 12, 1763-73		44
467	Efficacy of bortezomib as first-line treatment for patients with multiple myeloma. 2013 , 7, 53-73		19
466	MicroRNAs as Haematopoiesis Regulators. 2013 , 2013, 695754		71
465	Inhibition of glycogen synthase kinase-3 increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of STAT3. 2013 , 190, 6662-72		48
464	Fas apoptosis inhibitory molecule is upregulated by IGF-1 signaling and modulates Akt activation and IRF4 expression in multiple myeloma. 2013 , 27, 1165-71		20
463	PSGL-1/selectin and ICAM-1/CD18 interactions are involved in macrophage-induced drug resistance in myeloma. 2013 , 27, 702-10		98
462	Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. 2013 , 3, e121		48
461	Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma. <i>Blood</i> , 2013 , 121, 423-30	2.2	125
460	Retrospective analysis of 264 multiple myeloma patients. 2013 , 5, 707-713		8
459	The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. 2013 , 98, 1132-41		103
458	Multiple myeloma treatment in the elderly. 2013 , 2, 265-268		
457	An inverse switch in DNA base excision and strand break repair contributes to melphalan resistance in multiple myeloma cells. 2013 , 8, e55493		19
456	Frontline treatment of multiple myeloma in the elderly. 2013 , 19, 41-46		

455	Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. 2013,	
454	Multiple myeloma: an update. 2013, 28, 3-11	24
453	Multiple myeloma. 799-808	
452	NF-kappa B modulation is involved in celastrol induced human multiple myeloma cell apoptosis. 2014, 9, e95846	36
451	The choice of regimens based on bortezomib for patients with newly diagnosed multiple myeloma. 2014, 9, e99174	9
450	Subcutaneous bortezomib for multiple myeloma treatment: patients' benefits. 2014, 8, 939-46	10
449	Gamapatias Monoclonais de Significado Indeterminado: Critérios de Diagnóstico e Acompanhamento Clínico. 2014, 27, 661	
448	Treatment of multiple myeloma in Akita: features and outcomes in the era of novel agents. 2014, 54, 89-93	2
447	Patient, Physician and Contextual Factors Are Influential in the Treatment Decision Making of Older Adults Newly Diagnosed with Symptomatic Myeloma. 2014, 2, 34-47	22
446	Best treatment strategies in high-risk multiple myeloma: navigating a gray area. 2014, 32, 2125-32	20
445	Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Network. 2014, 74, 875-82	26
444	The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells. 2014, 4, e219	16
443	Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. 2014, 64, 422-44	61
442	Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma. 2014, 28, 894-903	18
441	Implications of heterogeneity in multiple myeloma. 2014, 2014, 232546	30
440	MicroRNA: important player in the pathobiology of multiple myeloma. 2014, 2014, 521586	40
439	Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. 2014, 99, 511-8	82
438	Induction of thymic stromal lymphopoietin in mesenchymal stem cells by interaction with myeloma cells. <i>Leukemia and Lymphoma</i> , 2014, 55, 2605-13	1.9 9

437	Risk adapted therapy for multiple myeloma: back to basics. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2219-20	1.9	9
436	MicroRNA theragnostics for the clinical management of multiple myeloma. 2014 , 28, 732-8		49
435	Cold-induced rashes. 2014 , 39, 250-2		
434	Celastrol inhibits lipopolysaccharide-induced angiogenesis by suppressing TLR4-triggered nuclear factor-kappa B activation. 2014 , 131, 102-11		33
433	Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN). 2014 , 37, 635-6, 638-44		7
432	Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study. 2014 , 12, 234		16
431	Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. 2014 , 20, 3989-4000		90
430	Hepcidin and GDF15 in anemia of multiple myeloma. 2014 , 100, 266-73		14
429	Circulating miRNAs: Potential Biomarkers for Diagnosis and Prognosis Prediction of Hematological Malignancies. 2014 , 02,		2
428	Therapeutic advancements in multiple myeloma. 2014 , 4, 241		40
427	Genetic and pharmacologic evidence that mTOR targeting outweighs mTORC1 inhibition as an antimyeloma strategy. 2014 , 13, 504-16		7
426	CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. 2014 , 28, 917-27		292
425	"Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. 2014 , 93, 129-39		36
424	Adhesion to fibronectin induces p27(Kip1) nuclear accumulation through down-regulation of Jab1 and contributes to cell adhesion-mediated drug resistance (CAM-DR) in RPMI 8,226 cells. 2014 , 386, 177-87		14
423	A structurally distinct human mycoplasma protein that generically blocks antigen-antibody union. 2014 , 343, 656-661		57
422	By inhibiting Src, verapamil and dasatinib overcome multidrug resistance via increased expression of Bim and decreased expressions of MDR1 and survivin in human multidrug-resistant myeloma cells. 2014 , 38, 121-30		40
421	The role of histone deacetylase inhibitors in patients with relapsed/refractory multiple myeloma. <i>Leukemia and Lymphoma</i> , 2014 , 55, 11-8	1.9	4
420	Myeloma genetics and genomics: practice implications and future directions. 2014 , 14, 436-40		13

419	Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients. 2014 , 177, 439-53		36
418	Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. 2014 , 89, 999-1009		123
417	Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. 2014 , 18, 947-61		112
416	A novel Bruton's tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity. 2014 , 28, 1892-901		33
415	Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. 2014 , 14, 356-69		6
414	The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. 2014 , 89, 34-40		29
413	Controversies in multiple myeloma: to transplant or not?. 2014 , 9, 360-7		2
412	Preclinical activity of the oral proteasome inhibitor MLN9708 in Myeloma bone disease. 2014 , 20, 1542-54		64
411	Response evaluation and monitoring of multiple myeloma. 2014 , 7, 33-42		7
410	The pivotal role of FDG-PET/CT in modern medicine. 2014 , 21, 232-49		77
409	Oral manifestation of multiple myeloma as plasmacytoma: A case report. 2014 , 26, 421-423		1
408	Comparison of 1-day vs 2-day dosing of high-dose melphalan followed by autologous hematopoietic cell transplantation in patients with multiple myeloma. 2014 , 49, 761-6		12
407	Does thrombopoiesis in multiple myeloma patients depend on the stage of the disease?. 2014 , 59, 166-71		6
406	Assessment of leptin and resistin levels in non-obese multiple myeloma patients and their relation with Ig level and disease stage. 2014 , 26, 61-6		8
405	Abdominal extraosseous lesions of multiple myeloma: imaging findings. 2014 , 65, 2-8		6
404	Exosomal miR-135b shed from hypoxic multiple myeloma cells enhances angiogenesis by targeting factor-inhibiting HIF-1. <i>Blood</i> , 2014 , 124, 3748-57	2.2	400
403	Triptolide induces apoptotic cell death of multiple myeloma cells via transcriptional repression of Mcl-1. 2014 , 44, 1131-8		18
402	How I treat relapsed myeloma. <i>Blood</i> , 2015 , 125, 1532-40	2.2	27

401	Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. <i>Blood</i> , 2015 , 126, 1443-51	2.2	55
400	The role of circulating miRNAs in multiple myeloma. 2015 , 58, 1262-9		16
399	Cancer-testis antigen MAGEC2 promotes proliferation and resistance to apoptosis in Multiple Myeloma. 2015 , 171, 752-62		8
398	Efficacy and Safety of Lenalidomide in the Treatment of Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials. 2015 , 128, 1215-22		13
397	Inducing cell cycle arrest and apoptosis by dimercaptosuccinic acid modified Fe ₃ O ₄ magnetic nanoparticles combined with nontoxic concentration of bortezomib and gambogic acid in RPMI-8226 cells. 2015 , 10, 3275-89		18
396	Icaritin suppresses multiple myeloma, by inhibiting IL-6/JAK2/STAT3. 2015 , 6, 10460-72		53
395	NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma. 2015 , 2015, 178698		50
394	Facial Swelling as a Primary Manifestation of Multiple Myeloma. 2015 , 2015, 319231		2
393	Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma. 2015 , 6, 3098-110		58
392	Preclinical and clinical development of an anti-kappa free light chain mAb for multiple myeloma. 2015 , 67, 89-94		8
391	Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma. 2015 , 11, 1643-58		
390	Factors regulating immunoglobulin production by normal and disease-associated plasma cells. 2015 , 5, 20-40		17
389	Analysis of clinical features, treatment response, and prognosis among 61 elderly newly diagnosed multiple myeloma patients: a single-center report. 2015 , 13, 239		5
388	Diagnosis and staging. 2015 , 15-28		
387	CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. 2015 , 12, 622-35		94
386	An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma. 2015 , 95, 426-35		8
385	The tumor microenvironment shapes hallmarks of mature B-cell malignancies. 2015 , 34, 4673-82		66
384	Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation. 2015 , 15, 17		40

383	Promising therapies in multiple myeloma. <i>Blood</i> , 2015 , 126, 300-10	2.2	71
382	The impact of one fraction of 8 Gy radiotherapy in palliative treatment of multiple myeloma patients with painful bone destructions. 2015 , 45, 364-71		6
381	An update on molecular biology and drug resistance mechanisms of multiple myeloma. 2015 , 96, 413-24		10
380	Modulation of the IL-6 Receptor Underlies GLI2-Mediated Regulation of Ig Secretion in Waldenström Macroglobulinemia Cells. 2015 , 195, 2908-16		14
379	Serum Free Light Chain Assessment Early After Stem Cell Transplantation as a Prognostic Factor in Multiple Myeloma. 2015 , 15, 541-5		5
378	Glucocorticoid Signaling. 2015 ,		8
377	Glucocorticoids and Cancer. 2015 , 872, 315-33		97
376	Bilateral pleural effusion as an initial manifestation of multiple myeloma: A case report and literature review. 2015 , 9, 1040-1042		7
375	Handbook of Multiple Myeloma. 2015 ,		3
374	Pre-treatment staging of multiple myeloma patients: comparison of whole-body diffusion weighted imaging with whole-body T1-weighted contrast-enhanced imaging. 2015 , 56, 733-8		22
373	Peptide-based immunotherapy in multiple myeloma. 2015 , 46, 248-253		
372	Impact of early use of lenalidomide and low-dose dexamethasone on clinical outcomes in patients with relapsed/refractory multiple myeloma. 2015 , 101, 37-45		8
371	Surgery for plasma cell neoplasia patients with spinal instability or neurological impairment caused by spinal lesions as the first clinical manifestation. 2015 , 24, 1761-7		9
370	TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities. 2015 , 106, 438-46		10
369	Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. 2015 , 169, 843-50		42
368	Pulmonary hypertension complicating multiple myeloma. 2015 , 5, 590-7		12
367	Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for multiple myeloma. 2015 , 102, 670-7		4
366	Clinical treatment of newly diagnosed multiple myeloma. 2015 , 8, 595-611		7

365	Novel Induction Regimens in Multiple Myeloma. 2015 , 10, 388-94	1
364	Pharmacologic screens reveal metformin that suppresses GRP78-dependent autophagy to enhance the anti-myeloma effect of bortezomib. 2015 , 29, 2184-91	74
363	Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma. 2015 , 36, 8545-52	20
362	Targeting executioner procaspase-3 with the procaspase-activating compound B-PAC-1 induces apoptosis in multiple myeloma cells. 2015 , 43, 951-962.e3	9
361	A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents. 2015 , 94, 145-51	11
360	Targeting the bone marrow microenvironment in multiple myeloma. 2015 , 263, 160-72	223
359	Multiple myeloma: a rare case in an 8-year-old child. 2015 , 15, e31-3	7
358	Three-drug versus two-drug induction therapy regimens for patients with transplant-eligible multiple myeloma. 2016 ,	78
357	Genetic aberrations in multiple myeloma characterized by clg-FISH: a Brazilian context. 2016 , 49, e5034	5
356	Lymphoproliferative Diseases. 2016 , 309-316	
355	Cytoplasmic calcium increase via fusion with inactivated Sendai virus induces apoptosis in human multiple myeloma cells by downregulation of c-Myc oncogene. 2016 , 7, 36034-36048	6
354	Comprehensive genomic profiling of IgM multiple myeloma identifies IRF4 as a prognostic marker. 2016 , 7, 47127-47133	5
353	Pegylated liposomal doxorubicin for multiple myeloma. 2016 ,	78
352	The Importance of an In-depth Study of Immunoglobulin Gene Rearrangements When Ascertaining the Clonal Relationship between Concomitant Chronic Lymphocytic Leukemia and Multiple Myeloma. 2016 , 7, 625	5
351	The KISS1 Receptor as an In Vivo Microenvironment Imaging Biomarker of Multiple Myeloma Bone Disease. 2016 , 11, e0155087	11
350	Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease. 2016 , 31, 1225-34	72
349	Cell autonomous and microenvironmental regulation of tumor progression in precursor states of multiple myeloma. 2016 , 23, 426-33	24
348	Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol. 2016 , 16, 387	4

347	Vaccination in Multiple Myeloma: Review of Current Literature. 2016 , 16, 495-502		19
346	How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. 2016 , 34, 4421-4430		15
345	Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen. 2016 , 51, 32-40		10
344	Sprouty2 regulates proliferation and survival of multiple myeloma by inhibiting activation of the ERK1/2 pathway in vitro and in vivo. 2016 , 44, 474-482.e2		6
343	Bortezomib-based chemotherapy to treat refractory angioimmunoblastic T-cell lymphoma: A case report and review of the literature. 2016 , 11, 2310-2314		4
342	Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. 2016 , 29, 639-652		67
341	A transplant "immunome" screening platform defines a targetable epitope fingerprint of multiple myeloma. <i>Blood</i> , 2016 , 127, 3202-14	2.2	5
340	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , 2016 , 127, 2693-700	2.2	57
339	Bortezomib-induced severe pulmonary complications in multiple myeloma: A case report and literature review. 2016 , 11, 2255-2260		11
338	Concise review - Treatment of multiple myeloma in the very elderly: How do novel agents fit in?. 2016 , 7, 383-9		8
337	IgM multiple myeloma with an extremely rare non-aggressive presentation: A case report. 2016 , 12, 2801-2803		1
336	Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management. 2016 , 91, 719-34		279
335	Immunoglobulin D Multiple Myeloma: Disease Profile, Therapeutic Response, and Survival. 2016 , 136, 140-6		10
334	Inhibition of multiple myeloma cell proliferation by ginsenoside Rg3 via reduction in the secretion of IGF-1. 2016 , 14, 2222-30		8
333	Identification of low-abundance proteins in serum via the isolation of HSP72 complexes. 2016 , 136, 214-21		4
332	Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. 2016 , 48, 1591-9		12
331	Clinical utility of morphology, immunohistochemistry, flow cytometry, and FISH analysis in monitoring of plasma cell neoplasms in the bone marrow. 2016 , 9, 9-18		5
330	Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells. 2016 , 38, 113-20		5

329	Early mortality in multiple myeloma: Experiences from a single institution. 2016 , 21, 392-8	11
328	miR-186 inhibits cell proliferation in multiple myeloma by repressing Jagged1. 2016 , 469, 692-7	28
327	Prognostic value of the inverse platelet to lymphocyte ratio (iPLR) in patients with multiple myeloma who were treated up front with a novel agent-containing regimen. 2016 , 95, 55-61	9
326	Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. 2017 , 35, 51-57	25
325	Direct measurement of hypoxia in a xenograft multiple myeloma model by optical-resolution photoacoustic microscopy. 2017 , 18, 101-105	14
324	Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects. 2017 , 15, 598-609	17
323	Trends in overall survival and costs of multiple myeloma, 2000-2014. 2017 , 31, 1915-1921	183
322	MicroRNA-1271 inhibits proliferation and promotes apoptosis of multiple myeloma cells through inhibiting smoothed-mediated Hedgehog signaling pathway. 2017 , 37, 1261-1269	18
321	Cytogenetic analysis of hematologic malignant diseases. 2017 , 499-575	1
320	Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3. 2017 , 77, 1283-1295	56
319	Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis. 2017 , 98, 563-568	6
318	Moving Beyond Maximum Tolerated Dose for Targeted Oncology Drugs: Use of Clinical Utility Index to Optimize Venetoclax Dosage in Multiple Myeloma Patients. 2017 , 102, 970-976	18
317	PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4. 2017 , 36, 4481-4497	13
316	Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma. 2017 , 36, 62	15
315	Potential roles of microRNAs and their target genes in human multiple myeloma. 2017 , 99, 178-185	6
314	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV. 2017 , 8, 861-877	43
313	Tariquidar sensitizes multiple myeloma cells to proteasome inhibitors via reduction of hypoxia-induced P-gp-mediated drug resistance. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2916-2925	1.9 23
312	Tumors of the Sacrum. 2017 ,	2

311	Deregulated expression of long non-coding RNA UCA1 in multiple myeloma. 2017 , 99, 223-233		31
310	Expression of Peripheral Blood miRNA-720 and miRNA-1246 Can Be Used as a Predictor for Outcome in Multiple Myeloma Patients. 2017 , 17, 415-423		8
309	Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device. 2017 , 7, 45681		26
308	Mechanisms of Resistance in Multiple Myeloma. 2018 , 249, 251-288		12
307	Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors. 2017 , 36, 585-598		7
306	Endothelial progenitor cells in multiple myeloma neovascularization: a brick to the wall. 2017 , 20, 443-462		23
305	The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in and models of multiple myeloma by blockade of Ikaros and MYC signaling. 2017 , 102, 1776-1784		34
304	p53 Deletion promotes myeloma cells invasion by upregulating miR19a/CXCR5. 2017 , 60, 115-122		7
303	LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma. 2017 , 8, e2975		112
302	Long non-coding RNA MALAT1 is an inducible stress response gene associated with extramedullary spread and poor prognosis of multiple myeloma. 2017 , 179, 449-460		53
301	Construction of a recombinant lentivirus-mediated shRNA expression vector targeting the human PSMD10 gene and validation of RNAi efficiency in RPMI-8226 multiple myeloma cells. 2017 , 38, 809-818		4
300	Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma. <i>Blood</i> , 2017 , 130, 1198-1204	2.2	46
299	Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future. 2017 , 17, 545-554		17
298	Melphalan hydrochloride for the treatment of multiple myeloma. 2017 , 18, 1127-1136		25
297	Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma. 2017 , 101, 81-88		25
296	MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 932-940	1.9	34
295	Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. 2017 , 31, 1123-1135		50
294	DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment. 2017 , 19, 972-981		12

293	BORTEZOMIB INDUCED SUBCONJUNCTIVAL HEMORRHAGE. 2017 , 10, 10	0
292	Replenishing exosomes from older bone marrow stromal cells with miR-340 inhibits myeloma-related angiogenesis. 2017 , 1, 812-823	57
291	Established and Novel Prognostic Biomarkers in Multiple Myeloma. 2017 , 37, 548-560	16
290	LncRNA PDIA3P interacts with c-Myc to regulate cell proliferation via induction of pentose phosphate pathway in multiple myeloma. 2018 , 498, 207-213	43
289	Proteomic characterization of Withaferin A-targeted protein networks for the treatment of monoclonal myeloma gammopathies. 2018 , 179, 17-29	13
288	The start of a new wave: Developments in proteasome inhibition in multiple myeloma. 2018 , 101, 220	12
287	Multiple Myeloma. 2018 , 463-483	
286	Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell. 2018 , 1869, 200-215	22
285	In silico screening of proteins targeting circulating miRNAs for improved diagnosis of multiple myeloma. 2018 , 497, 577-582	2
284	Transfusion management for patients taking an anti-CD38 monoclonal antibody. 2018 , 40, 25-29	5
283	Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF- κ B activity and increases drug resistance in multiple myeloma. 2018 , 293, 2452-2465	16
282	The bone-marrow niche in MDS and MGUS: implications for AML and MM. 2018 , 15, 219-233	81
281	HIF-2 β Is Involved in Mesenchymal Stromal Cell Angiogenesis in Multiple Myeloma Under Hypoxic Conditions. 2018 , 17, 1533033818764473	3
280	History of Multiple Myeloma. 2018 , 511-524	
279	Anthelmintic pyriminium pamoate blocks Wnt/ β -catenin and induces apoptosis in multiple myeloma cells. 2018 , 15, 5871-5878	13
278	A mandibular lesion revealing multiple myeloma. 2018 , 11, 157-162	
277	Modified HyperCVAD Versus Bortezomib-HyperCAD in Patients With Relapsed/Refractory Multiple Myeloma. 2018 , 18, e77-e84	7
276	Multiple Myeloma and Bone: The Fatal Interaction. 2018 , 8,	28

275	Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. 2018 , 14, 91-99	8
274	A historical perspective on milestones in multiple myeloma research. 2018 , 100, 221-228	5
273	Autologous Stem Cell Transplantation for Multiple Myeloma: Single Centre Experience from North India. 2018 , 34, 261-267	10
272	Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. <i>Leukemia and Lymphoma</i> , 2018 , 59, 941-949	1.9 21
271	Present and Future of Immunotherapy in the Management of Multiple Myeloma. 2018 , 14, 403-410	7
270	Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency. 2018 , 36, 2012-2016	1
269	Mechanisms of Drug Resistance in Cancer Therapy. 2018 ,	
268	The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis. 2018 , 2018, 3936706	1
267	Multiple myeloma and pepperpot skull. 2018 , 111, 917	
266	Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. 2018 , 20, 1309-1323	15
265	Pathway-structured predictive modeling for multi-level drug response in multiple myeloma. 2018 , 34, 3609-3615	2
264	Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model. 2018 , 431, 123-141	96
263	The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation. 2018 , 7, 3257	13
262	CLC5 Decreases the Sensitivity of Multiple Myeloma Cells to Bortezomib via Promoting Prosurvival Autophagy. 2018 , 26, 421-429	11
261	Can Neutrophil-to-Lymphocyte Ratio, Monocyte-to-Lymphocyte Ratio, and Platelet-to-Lymphocyte Ratio at Day +100 be used as a prognostic marker in Multiple Myeloma patients with autologous transplantation?. 2018 , 32, e13359	11
260	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. 2018 , 19,	12
259	Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression. 2018 , 18, 551	7
258	The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience. 2018 , 101, 354-361	7

257	miR-29b inhibits the progression of multiple myeloma through downregulating FOXP1. 2019 , 24, 32-38	12
256	Frontline treatment for transplant-eligible multiple myeloma: A 6474 patients network meta-analysis. 2019 , 37, 62-74	7
255	SOHO State of the Art Updates and Next Questions: T-Cell-Directed Immune Therapies for Multiple Myeloma: Chimeric Antigen Receptor-Modified T Cells and Bispecific T-Cell-Engaging Agents. 2019 , 19, 537-544	15
254	Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias. 2019 , 35, 673-682	2
253	Novel p97/VCP inhibitor induces endoplasmic reticulum stress and apoptosis in both bortezomib-sensitive and -resistant multiple myeloma cells. 2019 , 110, 3275-3287	13
252	IL-37: An anti-inflammatory cytokine with antitumor functions. 2019 , 2, e1151	6
251	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. 2019 , 5, 1293-1301	33
250	Targeting multiple myeloma with natural polyphenols. 2019 , 180, 465-485	12
249	Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple Myeloma Mouse Model. 2019 , 9,	9
248	What are the implications of cost for myeloma therapy?. 2019 , 12, 1005-1009	0
247	Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network. 2019 , 9, 83	4
246	Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. 2019 , 8,	17
245	Targeting MK2 Is a Novel Approach to Interfere in Multiple Myeloma. 2019 , 9, 722	3
244	Concentrations of Serum Free Light Chains in Kappa and Lambda Lesions in Light-Chain Myelomas. 2019 , 50, 189-193	9
243	Clinicopathological Profile of Myelomatous Pleural Effusion: Single-center Real-world Experience and Review of Literature. 2019 , 19, 183-189.e1	8
242	Methodological aspects of health-related quality of life measurement and analysis in patients with multiple myeloma. 2019 , 185, 11-24	12
241	The Effects of Proteasome Inhibitors on Telomerase Activity and Regulation in Multiple Myeloma Cells. 2019 , 20,	4
240	Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. 2019 , 10, 1121	49

239	A plasma cell-based pericardial effusion leading to tamponade in a patient with multiple myeloma - a case report and review of the literature. 2019 , 40, 41-46	3
238	Serum Free Light Chain Assay in Monoclonal Gammopathic Manifestations. 2019 , 50, 381-389	6
237	Clinical significance of circulatory microRNA-203 in serum as novel potential diagnostic marker for multiple myeloma. 2019 , 145, 1601-1611	23
236	Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: a retrospective single-center analysis. 2019 , 98, 1185-1195	13
235	Pomalidomide-dexamethasone for treatment of soft-tissue plasmacytomas in patients with relapsed / refractory multiple myeloma. 2019 , 102, 389-394	12
234	Multiple Myeloma and Fatty Acid Metabolism. 2019 , 3, e10173	15
233	Metabolic, Anti-apoptotic and Immune Evasion Strategies of Primary Human Myeloma Cells Indicate Adaptations to Hypoxia. 2019 , 18, 936-953	18
232	Autologous Lymphocyte Infusion Supports Tumor Antigen Vaccine-Induced Immunity in Autologous Stem Cell Transplant for Multiple Myeloma. 2019 , 7, 658-669	8
231	Prognostic model for multiple myeloma progression integrating gene expression and clinical features. 2019 , 8,	9
230	High expression of CHML predicts poor prognosis of multiple myeloma. 2019 , 10, 6048-6056	2
229	Novel Immunotherapeutic Agents for the Treatment of Multiple Myeloma. 2019 , 42, 317-329	6
228	Bone marrow niche in multiple myeloma and its precursor states.. 2019 , 3,	1
227	Prognostic Significance Of The Inflammatory Index-Based Scoring System In Patients Preliminarily Diagnosed With Multiple Myeloma In The Bortezomib-Based Chemotherapy Era. 2019 , 11, 9409-9420	3
226	F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System. 2019 , 46, 107-115	18
225	Rafoxanide, an organohalogen drug, triggers apoptosis and cell cycle arrest in multiple myeloma by enhancing DNA damage responses and suppressing the p38 MAPK pathway. 2019 , 444, 45-59	11
224	3-Bromopyruvate as a potent anticancer therapy in honor and memory of the late Professor Andr ^e Goffeau. 2019 , 36, 211-221	10
223	Bone marrow endothelial cells sustain a tumor-specific CD8 T cell subset with suppressive function in myeloma patients. 2019 , 8, e1486949	37
222	An improved variable selection procedure for adaptive Lasso in high-dimensional survival analysis. 2019 , 25, 569-585	5

221	The drug repurposing landscape from 2012 to 2017: evolution, challenges, and possible solutions. 2019 , 24, 789-795	44
220	Covariance-Insured Screening. 2019 , 132, 100-114	1
219	Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. 2020 , 105, 1650-1659	9
218	Targeting of stromal versican by miR-144/199 inhibits multiple myeloma by downregulating FAK/STAT3 signalling. 2020 , 17, 98-111	14
217	Strategies to improve patient-reported outcome completion rates in longitudinal studies. 2020 , 29, 335-346	11
216	MicroRNA-146b overexpression associates with deteriorated clinical characteristics, increased International Staging System stage, cacoethic chromosome abnormality, and unfavorable prognosis in multiple myeloma patients. 2020 , 34, e23168	2
215	Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse. 2020 , 188, 907-917	3
214	Paraproteins. 2020 , 53-58.e3	
213	Influence of the TGF- β Superfamily on Osteoclasts/Osteoblasts Balance in Physiological and Pathological Bone Conditions. 2020 , 21,	20
212	Long Noncoding RNA Is Regulated by Bromodomain Protein BRD4 in Multiple Myeloma and Is Associated with Disease Progression. 2020 , 21,	8
211	Myeloma cells induce the accumulation of activated CD94 ^{low} NK cells by cell-to-cell contacts involving CD56 molecules. 2020 , 4, 2297-2307	9
210	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. 2020 , 13, 94	76
209	Controversies in the use of new bone-modifying therapies in multiple myeloma. 2021 , 193, 1034-1043	6
208	Clinical and laboratory characteristics of lymphoid neoplasms in serous effusions: a single centre experience in China. 2020 , 48, 1173-1180	
207	Characterization of the role of Samsn1 loss in multiple myeloma development. 2020 , 2, 554-572	1
206	C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. 2020 , 18, 298	7
205	Targeting NF- κ B Signaling for Multiple Myeloma. <i>Cancers</i> , 2020 , 12,	6.6 9
204	Clinical impact of echocardiography-defined pulmonary hypertension on the clinical outcome in patients with multiple myeloma. 2020 , 99, e22952	2

203	Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma. 2020 , 20, 803		7
202	Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity. 2020 , 154, 816-827		1
201	Targeting NK Cell Inhibitory Receptors for Precision Multiple Myeloma Immunotherapy. 2020 , 11, 575609		11
200	The conditional censored graphical lasso estimator. 2020 , 30, 1273-1289		1
199	ATR addiction in multiple myeloma: synthetic lethal approaches exploiting established therapies. 2020 , 105, 2440-2447		6
198	Genetics of blood malignancies among Iranian population: an overview. 2020 , 15, 44		1
197	Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma. 2020 , 20, 489		1
196	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020 , 11, 2996	17.4	34
195	Hspa13 Promotes Plasma Cell Production and Antibody Secretion. 2020 , 11, 913		4
194	The Role of Imaging and Systemic Treatments in Myeloma: A Primer for Radiologists. 2020 , 214, 1321-1334		1
193	Data-Driven Statistical Modeling and Analysis of the Survival Times of Multiple Myeloma Cancer. 2020 , 14,		1
192	Proteomics-inspired precision medicine for treating and understanding multiple myeloma. 2020 , 5, 67-85		1
191	MIF as a biomarker and therapeutic target for overcoming resistance to proteasome inhibitors in human myeloma. <i>Blood</i> , 2020 , 136, 2557-2573	2.2	13
190	The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. 2020 , 9, 5869-5880		2
189	Bortezomib Treatment Modulates Autophagy in Multiple Myeloma. 2020 , 9,		11
188	Heat shock proteins as a new, promising target of multiple myeloma therapy. 2020 , 13, 117-126		4
187	Phosphoglycerate dehydrogenase promotes proliferation and bortezomib resistance through increasing reduced glutathione synthesis in multiple myeloma. 2020 , 190, 52-66		23
186	Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma. 2020 , 25, 357-367		7

185	Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma. 2020 , 1, 493-506		73
184	Self-reported health and survival in older patients diagnosed with multiple myeloma. 2020 , 31, 641-650		4
183	Quantification by Ultrafiltration and Immunofixation Electrophoresis Testing for Monoclonal Serum Free Light Chains. 2020 , 51, 592-600		5
182	A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma. <i>Blood</i> , 2020 , 135, 1232-1243	2.2	38
181	Historical perspectives in clinical pathology: Bence Jones protein-early urine chemistry and the impact on modern day diagnostics. 2021 , 74, 212-215		3
180	Challenges of interpreting the musculoskeletal manifestation of lymphoma: A case report. 2021 , 27, 243-246		
179	A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma. 2021 , 39, 41-50		7
178	Impact of MGUS and myeloma on skeletal health. 2021 , 1421-1437		
177	Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. 2021 , 21, e220-e226		3
176	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. 2021 , 113, 81-91		1
175	The Role of Targeted Therapy in Multiple Myeloma. 2021 , 1-15		
174	Health-related quality of life in patients with multiple myeloma participating in a multidisciplinary rehabilitation program. 2021 , 100, 2311-2323		3
173	Proteomic Alterations in Multiple Myeloma: A Comprehensive Study Using Bone Marrow Interstitial Fluid and Serum Samples. 2020 , 10, 566804		10
172	Immunomodulatory and Anti-Inflammatory Properties of Glucocorticoids. 2021 ,		
171	Prognostic and Predictive Factors in Newly Diagnosed Multiple Myeloma Patients with Early Mortality with Prediction Matrix and Three and Five-Year Overall Survival.		
170	Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat. 2021 , 4, 888-902		1
169	Clinical Characteristics and Risk Factors for Pleural Effusion in Patients with Multiple Myeloma. 2021 , 14, 649-657		0
168	Therapeutic Advances in Oncology. 2021 , 22,		5

167	Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels. 2021 , 138, 155358		10
166	Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy. 2021 , 12, 200		9
165	Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma. 2021 , 27, 273.e1-273.e5		1
164	Relapsing Multiple Myeloma Presenting as Cardiac Tamponade and Obstructive Uropathy. 2021 , 13, e14503		
163	Selection, Expansion, and Unique Pretreatment of Allogeneic Human Natural Killer Cells with Anti-CD38 Monoclonal Antibody for Efficient Multiple Myeloma Treatment. 2021 , 10,		3
162	Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors. 2021 , 15, 19-49		1
161	Current and Novel Alkylators in Multiple Myeloma. <i>Cancers</i> , 2021 , 13,	6.6	2
160	Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma. 2021 , 29, 6973-6980		0
159	Real-world evidence for carfilzomib dosing intensity on overall survival and treatment progression in multiple myeloma patients. 2021 , 10781552211015283		0
158	Case Report: Two Cases of Cryptosporidiosis in Heavily Pretreated Patients With Myeloma. 2021 , 21, e545-e547		1
157	Initial Therapeutic Approaches to Patients with Multiple Myeloma. 2021 , 38, 3694-3711		4
156	An Historical Overview of the Amyloidoses.		
155	Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016. 2021 , 11, 17272		3
154	Epidemiology, genetics and treatment of multiple myeloma and precursor diseases. 2021 , 149, 1980-1996		5
153	RAR α activation sensitizes human myeloma cells to carfilzomib treatment through OAS-RNase L innate immune pathway. <i>Blood</i> , 2021 ,	2.2	1
152	NK cell surveillance of hematological malignancies. Therapeutic implications and regulation by chemokine receptors. 2021 , 80, 100968		1
151	Real-Life Experience with Pomalidomide plus Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma: A Retrospective and Prospective Study. 2021 , 57,		0
150	Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma. 2021 , 11, 16460		

149	Real-Life Experience With First-Line Therapy Bortezomib Plus Melphalan and Prednisone in Elderly Patients With Newly Diagnosed Multiple Myeloma Ineligible for High Dose Chemotherapy With Autologous Stem-Cell Transplantation. 2021 , 8, 712070	2
148	Evaluation of Diffuse Bone Marrow Infiltration Pattern in Monoclonal Plasma Cell Diseases by Quantitative Whole-body Magnetic Resonance Imaging. 2021 ,	
147	Tissue-resident macrophages promote early dissemination of multiple myeloma via IL-6 and TNF β . 2021 , 5, 3592-3608	2
146	Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma. <i>Cancers</i> , 2021 , 13,	6.6 3
145	ALCAM-EGFR interaction regulates myelomagenesis. 2021 , 5, 5269-5282	1
144	Pathogenesis and treatment of multiple myeloma bone disease. 2021 , 57, 164-173	0
143	Multiple Myeloma. 2019 ,	2
142	Dissecting racial disparities in multiple myeloma. 2020 , 10, 19	34
141	Cell Trafficking in Multiple Myeloma. 2012 , 3,	8
140	Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines. 2011 , 6, e27707	20
139	Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma. 2012 , 7, e31998	12
138	Bortezomib reduces the tumorigenicity of multiple myeloma via downregulation of upregulated targets in clonogenic side population cells. 2013 , 8, e56954	38
137	Ectopic microRNA-150-5p transcription sensitizes glucocorticoid therapy response in MM1S multiple myeloma cells but fails to overcome hormone therapy resistance in MM1R cells. 2014 , 9, e113842	31
136	Abnormal repression of SHP-1, SHP-2 and SOCS-1 transcription sustains the activation of the JAK/STAT3 pathway and the progression of the disease in multiple myeloma. 2017 , 12, e0174835	24
135	Effects of intratesticular injection of zinc-based solution in rats in combination with anti-inflammatory and analgesic drugs during chemical sterilization. 2018 , 11, 649-656	1
134	Oligoclonal Pattern/Abnormal Protein Bands in Post-Treatment Plasma Cell Myeloma Patients: Implications for Protein Electrophoresis and Serum Free Light Chain Assay Results. 2017 , 9, 671-679	16
133	Prospective Identification of Oligoclonal/Abnormal Band of the Same Immunoglobulin Type as the Malignant Clone by Differential Location of M-Spike and Oligoclonal Band. 2017 , 9, 826-830	3
132	Serum Free Light Chains in Neoplastic Monoclonal Gammopathies: Relative Under-Detection of Lambda Dominant Kappa/Lambda Ratio, and Underproduction of Free Lambda Light Chains, as Compared to Kappa Light Chains, in Patients With Neoplastic Monoclonal Gammopathies. 2018 , 10, 562-569	9

131	NF-κB Activation in U266 Cells on Mesenchymal Stem Cells. 2016 , 6, 415-422	3
130	Biology and bioinformatics of myeloma cell. 2012 , 18, 30-41	9
129	Unique Pattern of Overexpression of Raf-1 Kinase Inhibitory Protein in Its Inactivated Phosphorylated Form in Human Multiple Myeloma. 2011 , 2,	9
128	Multiple myeloma cell lines and primary tumors proteoma: protein biosynthesis and immune system as potential therapeutic targets. 2015 , 6, 462-471	15
127	Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma. 2013 , 4, 1008-18	24
126	Evaluation of in vitro effects of various targeted drugs on plasma cells and putative neoplastic stem cells in patients with multiple myeloma. 2016 , 7, 65627-65642	6
125	Recurrent mutations of MAPK pathway genes in multiple myeloma but not in amyloid light-chain amyloidosis. 2016 , 7, 68350-68359	4
124	A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo. 2014 , 5, 3836-48	13
123	Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. 2017 , 8, 41091-41101	12
122	A serum microRNA signature associated with complete remission and progression after autologous stem-cell transplantation in patients with multiple myeloma. 2015 , 6, 1874-83	36
121	The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma. 2015 , 6, 23609-30	63
120	Serum high expression of miR-214 and miR-135b as novel predictor for myeloma bone disease development and prognosis. 2016 , 7, 19589-600	38
119	MiR-181a functions as an oncogene by regulating CCND1 in multiple myeloma. 2020 , 20, 758-764	3
118	Myeloma prognostic index at diagnosis might be a prognostic marker in patients newly diagnosed with multiple myeloma. 2017 , 32, 711-721	11
117	Modified dose of melphalan-prednisone in multiple myeloma patients receiving bortezomib plus melphalan-prednisone treatment. 2019 , 34, 1333-1346	1
116	Newly established stem cell transplant program: 100 days follow-up of patients and its comparison with published Indian literature. 2016 , 37, 168-73	2
115	"Punched out" multiple myeloma lytic lesions in the skull. 2016 , 6, 7-9	4
114	Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. 2019 , 10, 303-306	3

- 113 Treatment approach of nontransplant patients with multiple myeloma. **2014**, 26, 348-51 6
- 112 Uncommon Presentations of Multiple Myeloma. **2020**, 12, e8400 4
- 111 Thalidomide Therapy for Refractory Multiple Myeloma. **2009**, 58, 97-103
- 110 Immunological manifestations of haematological disease. **2009**, 293-305
- 109 Mobilization Strategies for Autologous Collection and Cryopreservation of Peripheral Blood Stem Cells in Patients with Lymphoproliferative Diseases. **2009**, 2, 209-216
- 108 Unusual manifestation of multiple myeloma: focal affection of central nervous system in a patient with chronic lymphocytic leukaemia. **2009**, 153, 271-3 1
- 107 Treatment of Multiple Myeloma: A Comprehensive Review. **2009**, 3, 65-75
- 106 Multiple Myeloma and Plasma Cell Dyscrasias. **2010**, 640-666
- 105 Clinical Presentation of Myeloma Bone Disease. **2010**, 1-13
- 104 Complicaciones respiratorias de las enfermedades hematológicas. **2010**, 528-535
- 103 Radiation Therapy in Multiple Myeloma. **2010**, 91-100 1
- 102 Overview of the Lymphoid Neoplasms. **2012**, 3-39
- 101 Allogeneic hematopoietic cell transplant for multiple myeloma using reduced intensity conditioning therapy, 1998-2006: factors associated with improved survival outcome. *Leukemia and Lymphoma*, 1-9 1,9
- 100 MGUS: Proposal for outpatient management. **2012**, 1, 5
- 99 Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. **2012**, e1-e80
- 98 Genetic and Environmental Determinants in Multiple Myeloma: Implications for Therapy. **2012**, 53-82
- 97 Migration and Homing in Multiple Myeloma. **2013**, 215-239
- 96 The Bone Marrow Microenvironment: Novel Targets to Circumvent Minimal Residual Disease and Drug Resistance in Multiple Myeloma. **2013**, 141-168

- 95 Differential protein expression profile between CD20 positive and negative cells of the NCI-H929 cell line. **2012**, 13, 5409-13
- 94 Differential Regulation of Cytochrome C Release in Dexamethasone-Resistant 7TD1 Cells. **2013**, 04, 835-842 1
- 93 Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India. **2015**, 9, XC01-XC04
- 92 Multiple Myeloma. **2015**, 760-763
- 91 Multiple Myeloma. **2016**, 294-299
- 90 Multiple Myeloma. **2016**, 414
- 89 Plasma Cell Neoplasm Manifesting Initially as a Sub-Cutaneous Supra-Orbital Swelling. **2016**, 61, 120 1
- 88 Lymphoma and Myeloma of the Sacrum. **2017**, 227-235
- 87 Multiple myeloma CD4+ regulatory T helperin role **2017**, 42, 546-551
- 86 Plasma cell neoplasms in HIV-Infected Patients: A Literature Review and Case Series. **2017**, 10, 464-470 1
- 85 The Evolution of Intracardiac Hemodynamics Post Autologous Stem Cell Transplant in a Case of Multiple Myeloma Associated with Severe Tricuspid and Mitral Valve Insufficiency. **2017**, 2, 45-47 1
- 84 Predicting Future Bone Infiltration Patterns in Multiple Myeloma. **2018**, 76-84
- 83 Intracranial Calcification Masquerading as Hemorrhage in a Patient with Multiple Myeloma Presenting with Facial Neuropathy. **2018**, 10, e2841
- 82 Nursing support during treatment of multiple myeloma with proteasome inhibitors. **2018**,
- 81 Multiple Myeloma Secondary to HIV Infection, Revealed by Renal Failure: About a Case. **2019**, 09, 20-25
- 80 BENCE JONES PROTEIN THE FIRST TUMOUR MARKER IN HISTORY OF MEDICINE. **2019**, 58, 125-130
- 79 The Effect of Ras Homolog C/Rho-Associated Coiled-Protein Kinase (Rho/ROCK) Signaling Pathways on Proliferation and Apoptosis of Human Myeloma Cells. **2019**, 25, 7605-7616 3
- 78 Chemotherapy-Induced Peripheral Neuropathy and its Impact on Health-Related Quality of Life among Multiple Myeloma Patients: A Single-Center Experience. **2020**, 26, 506-511

77	Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma.	
76	Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma.	
75	Components of metabolic syndrome in patients with multiple myeloma and smoldering multiple myeloma.	
74	A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. 2020,	3
73	Survival Analysis of Multiple Myeloma Cancer (MMC) Using the Cox-Proportional Hazard Model. 2020, 5,	1
72	Parametric and Non-Parametric Analysis of the Survival Times of Patients with Multiple Myeloma Cancer. 2020, 10, 118-134	1
71	Hematological Neoplasia. 2008, 400-526	
70	The Clinical Characteristics of Multiple Myeloma in the Acute Care Setting: Case Presentation and Clinical Recommendations. 2020, 12, e10463	
69	Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. 2010, 10, 4	29
68	Composite patient reports: a laboratory informatics perspective and pilot project for personalized medicine and translational research. 2009, 2009, 39-43	1
67	Osteogenic inhibition in multiple myeloma. 2013, 15, 266-71	11
66	Multiple myeloma relapse following autologous stem cell transplant presenting with diffuse pulmonary nodules. 2013, 13, 553-7	3
65	Myelomatous plasma cells display an aberrant gene expression pattern similar to that observed in normal memory B cells. 2015, 5, 386-95	
64	Long-term disease control in a refractory multiple myeloma patient treated with bortezomib mono-therapy: a case report and review of literature. 2015, 8, 19629-31	2
63	Levels of interleukin-16 in peripheral blood of 52 patients with multiple myeloma and its clinical significance. 2015, 8, 22520-4	2
62	An Unusual Cause of Altered Mental Status in Multiple Myeloma: An Extrasosseous Manifestation. 2016, 75, 109-12	1
61	Prognostic Value of IL-10 and Its Relationship with Disease Stage in Iranian Patients with Multiple Myeloma. 2018, 19, 27-32	2
60	[Myeloid-derived suppressor cells in peripheral blood of multiple myeloma]. 2017, 38, 545-547	

59	[Efficacy and prognosis of PAD combination therapy for fifty-six previously untreated patients with multiple myeloma]. 2016 , 37, 520-2	
58	[Cdc37 Contributes to bortezomib resistance in multiple myeloma via autophagy]. 2020 , 41, 583-588	
57	Multiple myeloma.	
56	Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group. 2021 , 10,	
55	Assessment of Bone Marrow Biopsy and Cytogenetic Findings in Patients with Multiple Myeloma. 2021 ,	
54	Development of a new risk stratification system for patients with newly diagnosed multiple myeloma using R-ISS and F-FDG PET/CT. 2021 , 11, 190	2
53	Knockdown of lncRNA BDNF-AS inhibited the progression of multiple myeloma by targeting the miR-125a/b-5p-BCL2 axis.. 2022 , 19, 3	0
52	miR-19a-3p Functions as an Oncogene by Regulating FBXO32 Expression in Multiple Myeloma. 2021 , 38, 43-49	1
51	Ferroptosis: Redox Imbalance and Hematological Tumorigenesis.. 2022 , 12, 834681	3
50	Single Cell Characterization of Myeloma and its Precursor Conditions Reveals Transcriptional Signatures of Early Tumorigenesis.	
49	Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.. 2022 , 12, 820768	0
48	A novel silicone derivative of natural osalmid (DCZ0858) exerts anti-multiple myeloma activity by promoting cell apoptosis and inhibiting cell cycle and mTOR signaling. 2021 , 13, 11439-11449	1
47	Splicing factor arginine/serine-rich 8 promotes multiple myeloma malignancy and bone lesion through alternative splicing of CACYBP and exosome-based cellular communication.. 2022 , 12, e684	1
46	Aqueous Extract of Reprogramming Macrophage Polarization by Activating TLR4-NF-B Signaling Pathway.. 2022 , 15, 1027-1046	1
45	Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen.. 2022 ,	0
44	Regional differences in treatment and outcome for myeloma patients in Sweden: A population based Swedish myeloma register study.. 2022 , e1614	
43	Extracellular vesicles mediate the communication between multiple myeloma and bone marrow microenvironment in a NOTCH dependent way.. 2022 ,	1
42	Detecting Multiple Myeloma Infiltration of the Bone Marrow on CT Scans in Patients with Osteopenia: Feasibility of Radiomics Analysis.. 2022 , 12,	0

41	Inhibition of Cytosolic Phospholipase A2 Induces Apoptosis in Multiple Myeloma Cells.. 2021 , 26,		0
40	Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and multiple myeloma. 155-183		
39	Image_1.pdf. 2020 ,		
38	Table_1.XLSX. 2020 ,		
37	Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones. 2022 , 29, 2954-2972		0
36	Ecatenin inhibitors ICG-001 and pyrvinium sensitize bortezomib-resistant multiple myeloma cells to bortezomib. 2022 , 24,		0
35	Myelomatous pleural effusion.		
34	Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors. 2022 , 12,		1
33	SIRT2-KLF4 Interactions are Critical for Myeloma Survival and Migration. 2022 , 2022, 1-6		0
32	Perikard Tutulumu Olan Multiple Myelom Olgusu.		
31	Clinical Management of Triple-Class Refractory Multiple Myeloma: A Review of Current Strategies and Emerging Therapies. 2022 , 29, 4464-4477		1
30	Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm. 12,		0
29	Thromboprophylaxis in multiple myeloma. <i>Leukemia and Lymphoma</i> , 1-9	1.9	1
28	What's Old is New: The Past, Present and Future Role of Thalidomide in the Modern-Day Management of Multiple Myeloma. <i>Targeted Oncology</i> ,	5	0
27	Blocking glycine utilization inhibits multiple myeloma progression by disrupting glutathione balance. <i>Nature Communications</i> , 2022 , 13,	17.4	4
26	High-Throughput CRISPR Screening in Hematological Neoplasms. <i>Cancers</i> , 2022 , 14, 3612	6.6	0
25	Case report: Thoracic and lumbar plasma cell myeloma mimicking hemangiomas on MRI and 18F-FDG PET/CT. 9,		
24	High Expression of the Costimulatory Checkpoint Factor DNAM-1 by CD4+ T-Cells From Multiple Myeloma Patients Refractory to Daratumumab-Containing Regimens.		

- 23 Circulating miR-448 acts as a potential diagnostic biomarker for multiple myeloma. **2022**, 27, 847-852
- 22 Characterizing the role of the immune microenvironment in multiple myeloma progression at a single cell level. ○
- 21 Myeloma, melphalan, and the taste of transplantation. ○
- 20 Cold Atmospheric Plasma Suppressed MM In Vivo Engraftment by Increasing ROS and Inhibiting the Notch Signaling Pathway. **2022**, 27, 5832 ○
- 19 Decompensated Heart Failure as the Initial Presentation of Multiple Myeloma: A Case Report. **2022**, ○
- 18 Preclinical Pharmacokinetics, Tissue Distribution and in vitro Metabolism of FHND6091, a Novel Oral Proteasome Inhibitor. Volume 16, 3087-3107 ○
- 17 From Nature to Synthetic Compounds: Novel 1(N),2,3 Trisubstituted-5-oxopyrrolidines Targeting Multiple Myeloma Cells. **2022**, 23, 13061 1
- 16 DAZAP1 facilitates the alternative splicing of KITLG to promote multiple myeloma cell proliferation via ERK signaling pathway. **2022**, 14, 7972-7985 ○
- 15 Advances in the molecular characterization of multiple myeloma and mechanism of therapeutic resistance. 12, ○
- 14 Tumor immune cell infiltration score based model predicts prognosis in multiple myeloma. **2022**, 12, ○
- 13 Extracellular Vesicles Isolated from Plasma of Multiple Myeloma Patients Treated with Daratumumab Express CD38, PD-L1, and the Complement Inhibitory Proteins CD55 and CD59. **2022**, 11, 3365 ○
- 12 Generation of the human pluripotent stem cell lines KUMi005-A from a patients with multiple myeloma. **2022**, 65, 102939 ○
- 11 Analysis of signaling cascades from myeloma cells treated with pristimerin. **2022**, ○
- 10 Identification and in-vitro analysis of potential proteasome inhibitors targeting PSM β for multiple myeloma. **2023**, 157, 113963 ○
- 9 Identification of Ubiquitination-Associated Proteins Using 2D-DIGE. **2023**, 83-96 ○
- 8 Single cell characterization of myeloma and its precursor conditions reveals transcriptional signatures of early tumorigenesis. **2022**, 13, ○
- 7 HAPLN1 confers multiple myeloma cell resistance to several classes of therapeutic drugs. **2022**, 17, e0274704 ○
- 6 Pneumonitis associated with bortezomib in a patient with multiple myeloma. 107815522211437 ○

- 5 Clinical significance of human endogenous retrovirus K (HERV-K) in multiple myeloma progression. 1
- 4 MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression. **2023**, 14, 100 0
- 3 Vagal Nerve Activity Predicts Prognosis in Diffused Large B-Cell Lymphoma and Multiple Myeloma. **2023**, 12, 908 0
- 2 Myeloma Microenvironmental TIMP1 Induces the Invasive Phenotype in Fibroblasts to Modulate Disease Progression. **2023**, 24, 2216 0
- 1 Skull Base and Bone. **2023**, 167-211 0